Skip to main content
Laszlo Urban on Muck Rack

Laszlo Urban

Cambridge
As seen in: Nature, The BMJ, BioRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Laszlo

Contact Laszlo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

1492 Telomere-targeting agent THIO in sequence with cemiplimab demonstrates long-term therapeutic benefits beyond treatment cessation - A phase 2 THIO-101 trial in advanced ICI resistant NSCLC patients | Journal for ImmunoTherapy of Cancer

|
By Csoszi Tibor, Laszlo Urban, Tunde Nagy
| The BMJ Verified
http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial.
Open in Who Shared View Duplicates (151) Issue with article?

A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs - Nature Communications

|
By Laszlo Urban
| Nature Verified
Abstract In vitro secondary pharmacology assays are an important tool for predicting clinical adverse drug reactions (ADRs) of investigational drugs. We created the Secondary Pharmacology Database (SPD) by testing 1958 drugs using 200 assays to validate target-ADR associations. Compared to public and subscription resources, 95% of all and 36% of active (AC50 < 1 µM) results are unique to SPD, with bias towards higher activity in public resources.
Open in Who Shared Issue with article?

A novel preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs

|
By Dimitar Yonchev, Alexander Fekete, Laszlo Urban
| BioRxiv
Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.
Open in Who Shared View Duplicates (686) Issue with article?
See all 3 articles